Dental Tribune U.S.Edition No.3, 2016

Dental Tribune U.S. Edition | March 2016 a13 INDUSTRY NEWS Ad Visalys® Core, the new product from Kettenbach LP (www.kettenbachusa.com), represents the next genera- tion of core buildup materials, according to the compa- ny. The most recent addition to the Visalys family is a dual-curing core buildup material with unique Active- Connect Technology (ACT) to ensure a reliable bond with all common adhesives — without an additional activator. The product was unveiled at the 2015 Inter- national Dental Show (IDS) in Germany. Visalys Core is the first core buildup material from Kettenbach. The fluoride-containing, dual-curing composite was developed for the fabrication of radi- opaque core buildups and core fillings and for cement- ing root posts. According to the company, the Active-Connect Tech- nology, unique in the market, enables the material to bond actively with all common light-curing and dual- curing, single-step and multistep adhesives, without an additional activator. The advantage for users is that it enables them to use the bonding agent they are used to — whether it is light-curing or dual-curing — or a single- or multi-bottle system. Firm foundation: Stable and precise According to the company, the technology simply provides a firm foundation — stable and precise. The company reports that Visalys Core ensures easy and reliable handling with “excellent positional stability.” At the same time, it exhibits good flowability and low extrusion force. The compressive strength results in a stable monoblock and a secure bond. Optional light-curing allows the procedure to be continued immediately. Reliable self-curing provides for dependable strength even on the cavity floor and in root canals. Excellent polishing characteristics en- sure precise preparation; even without light-curing, the smear layer is minimal. The product is also free of Bisphenol A and its derivatives. Visalys Core is available in dentin and white shades in a 5 ml double syringe and in a 25 ml cartridge. For detailed information about Visalys Core, visit the Kettenbach website at www.kettenbachusa.com. About Kettenbach Kettenbach (Huntington Beach, Calif.) is the exclu- sive U.S. distributor for Kettenbach GmbH & Co. KG (Eschenburg, Germany). Founded by August Ketten- bach in 1944, Kettenbach GmbH was created for the development and marketing of medical and dental products. Today, the company is one of the leading interna- tional producers of dental impression materials and is also known in other surgical areas of medicine. Brands include Panasil VPS Impression Material, Identium VSXE Impression Material, Futar Bite Material, Silginat Alternative Alginate, Visalys Temp Material, Mucopren Resilient Liner and Visalys Veneers. For more information about Kettenbach LP products, you can call (877) 532-2123 or visit www.kettenbachusa. com. (Source: Kettenbach) Kettenbach’s Visalys Core uses ‘Active-Connect Technology,’ described by the company as being unique in the market. The technology enables the buildup material to bond actively with all common light-curing and dual-curing, single-step and multistep adhesives — without an additional activator. Photo/Provided by Kettenbach Fluoride-containing Visalys Core dual-curing composite is for fabrication of radiopaque core buildups, core fillings and cementing root posts “ PROTEIN, page A12 novel ability of NELL-1 to stimulate bone growth and repress the formation of fat may highlight new treat- ment approaches for osteoporosis and other therapies for bone loss,” Soo said. Previous and present studies demonstrate a strong rationale for combining NELL-1 with BMP2 to signifi- cantly improve the safety and efficacy of current bone regeneration options. The combination of NELL-1 and BMP2 may be particularly valuable for healing local bone defects in people who have osteoporosis or for those taking medications, such as steroids, that can in- hibit bone growth. “Dr. Ting and his research team have made a very valuable discovery for the field of bone regeneration,” said Dr. No-Hee Park, dean of the UCLA School of Den- tistry. “The researchers’ findings have potential to help millions who suffer from osteoporosis and other bone defects.” NELL-1 is also currently in development as a single therapy for systemic treatment of osteoporosis. NELL-1, when given systemically, does not appear to induce ec- A new generation of core buildup material topic bone. In contrast, because of its known capacity to induce unwanted bone, BMP2 may not be as appropri- ate for systemic administration. The study’s other authors are Jia Shen, Dr. Aaron James, Dr. Xinli Zhang, Dr. Janette Zara, Greg Asatrian, Michael Chiang, Min Lee, Alan Nguyen, Kevin Lee, Ronald Siu, Dr. Sotirios Tetradis, Kevork Khadarian and Shen Pang, all of UCLA. The study was supported in part by a California In- stitute for Regenerative Medicine Early Translational II Research Award (TR2-01821); National Institute of Den- tal and Craniofacial Research grants (R21 DE0177711, RO1 DE01607 and RO1 AR061399-01A1); a UC Discovery Grant (07-10677) and a Broad Stem Cell Research Center Innovation Award. Several of the study authors, including Xinli Zhang, Ting and Soo, are inventors on NELL-1-related patents and are founders and/or board members of Bone Bio- logics Corporation, which sublicenses NELL-1 patents from the UC Regents. The regents also hold equity in the company. (Source: UCLA) Hinman BOOTH NO. 1144

Dental Tribune U.S.Edition No.3, 2016

Pages Overview